FTNT — long thesis
Thesis
Fortinet delivered a massive Q1 2026 beat-and-raise: revenue $1.85B (vs $1.73B expected), non-GAAP EPS $0.82 (vs $0.62 expected), billings grew 31% YoY, and product revenue surged 41%. Management raised full-year 2026 guidance to $7.71-7.87B revenue and $3.10-3.16 EPS, above prior consensus of $7.6B and $2.98. Record free cash flow of $1.01B in Q1. The stock gapped up ~22% to ~$110 after trading at $90 pre-earnings. Cybersecurity demand is accelerating from AI data center buildout, OT security, and sovereign SASE requirements. Multiple analysts raised PTs (TD Cowen to $125, Truist to $120, Barclays to $115, Rosenblatt to $125). However, at current levels (~$110), the stock trades at ~33x projected 2026 EPS, a premium to its 3-year average of ~27x. Consensus analyst PT of $93 is actually BELOW current price, suggesting the post-earnings move has overshot. This is a watchlist-then-pullback thesis — do not chase the gap.
Triggers
Entry: Enter on pullback of 10-15% from post-earnings high ($110). Target entry in the $94-99 range, which would be closer to the updated analyst consensus PTs and near the historical P/E norm. Alternatively, enter if the stock consolidates above $105 for 5+ sessions with high volume, confirming the new base. Position size ~1-2% of portfolio given the post-gap entry risk.
Exit: If entered on pullback, take profits at 15-20% gain from entry. Exit if Q2 2026 results show billings growth decelerating below 20% or if full-year guidance is reduced. Trim if position exceeds 3% of portfolio.
Invalidation: Stock breaks below $85 (pre-earnings level) on fundamental concerns; billings growth decelerates below 20% YoY; cybersecurity spending cycle reverses; enterprise demand weakens significantly; competitive pressure from PANW/CRWD materially erodes market share.
Cited evidence
News
- BCRX These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
- BLZE Backblaze Stock Seesaws After AI-Fueled Earnings Rally, Raised Outlook